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Germline specification in mammals occurs through an inductive process whereby competent
cells in the post-implantation epiblast differentiate into primordial germ cells (PGC). The
intrinsic factors that endow epiblast cells with the competence to respond to germline
inductive signals remain unknown. Single-cell RNA sequencing across multiple stages of an
in vitro PGC-like cells (PGCLC) differentiation system shows that PGCLC genes initially
expressed in the naïve pluripotent stage become homogeneously dismantled in germline
competent epiblast like-cells (EpiLC). In contrast, the decommissioning of enhancers asso-
ciated with these germline genes is incomplete. Namely, a subset of these enhancers partly
retain H3K4me1, accumulate less heterochromatic marks and remain accessible and
responsive to transcriptional activators. Subsequently, as in vitro germline competence is lost,
these enhancers get further decommissioned and lose their responsiveness to transcriptional
activators. Importantly, using H3K4me1-deficient cells, we show that the loss of this histone
modification reduces the germline competence of EpiLC and decreases PGCLC differentiation
efficiency. Our work suggests that, although H3K4me1 might not be essential for enhancer
function, it can facilitate the (re)activation of enhancers and the establishment of gene
expression programs during specific developmental transitions.
https://doi.org/10.1038/s41467-021-26065-6 OPEN
1 Center for Molecular Medicine Cologne (CMMC), University of Cologne, Cologne, Germany. 2 Department of Internal Medicine 2, University Hospital
Cologne, Cologne, Germany. 3 Cluster of Excellence Cellular Stress Responses in Aging-Associated Diseases (CECAD), University of Cologne,
Cologne, Germany. 4 Institute of Biomedicine and Biotechnology of Cantabria (IBBTEC), CSIC/University of Cantabria, Santander, Spain. 5 Department of
Biology, Massachusetts Institute of Technology, Cambridge, MA, USA. 6 Epigenetics Programme, Babraham Institute, Cambridge, UK. 7 Department of
Chemical and Systems Biology, Stanford University School of Medicine, Stanford, USA. 8 Centro Nacional de Investigaciones Cardiovasculares (CNIC),
Madrid, Spain. 9 Institute of Human Genetics, Heidelberg University Hospital, Heidelberg, Germany. 10 Erasmus University Medical Center Rotterdam, Center
for Biomics, Rotterdam, the Netherlands. 11 Centro de Biología Molecular Severo Ochoa (CBMSO), CSIC-UAM, Madrid, Spain. 12 Department of
Developmental Biology, Stanford University School of Medicine, Stanford, USA. 13 Howard Hughes Medical Institute, Stanford University School of Medicine,
Stanford, USA. 14 Centre for Trophoblast Research, University of Cambridge, Cambridge, UK. 15Wellcome Trust Sanger Institute, Cambridge, UK.
✉email: tbleckwe@uni-koeln.de; alvaro.rada@unican.es









Competence can be defined as the ability of a cell to dif-ferentiate towards a specific cell fate in response tointrinsic and extrinsic signals1. While the extracellular
signals involved in the induction of multiple cell fates have been
described2, the intrinsic factors that determine the cellular com-
petence to respond to those signals remain elusive. One major
example illustrating the dynamic and transient nature of com-
petence occurs early during mammalian embryogenesis, as the
primordial germ cells (PGC), the precursors of the gametes,
become specified. In mice, following implantation and the exit of
naïve pluripotency (E4.5–E5.5), PGC are induced from the epi-
blast around E6.0–E6.25 at the proximo-posterior end of the
mouse embryo3. The induction of PGC occurs in response to
signals emanating from the extraembryonic tissues surrounding
the epiblast: BMP4 from the extraembryonic ectoderm and
WNT3 from the visceral endoderm4. Furthermore, regardless of
their position within the embryo, formative epiblast cells
(~E5.5–6.25)5–7 are germline competent when exposed to
appropriate signals, but this ability gets lost as the epiblast pro-
gresses towards a primed pluripotency stage (>E6.5)4. However,
the intrinsic factors that confer germline competence on the
formative but not the primed epiblast cells remain obscure8,9,
partly due to the limited cell numbers that can be obtained in vivo
from mouse peri-implantation embryos (E4.5–E6.5). These lim-
itations were mitigated by a robust in vitro differentiation system
whereby mouse embryonic stem cells (ESC) grown under 2i
conditions (naïve pluripotency) can be sequentially differentiated
into EpiLC and PGCLC that resemble the formative epiblast and
E9.5 PGC, respectively10. This system facilitated the mechanistic
and genomic characterization of transcription factors (TFs)11–13
and epigenetic reprogramming events14–16 previously shown to
be involved in PGC specification in vivo17,18.
Using the PGCLC in vitro differentiation system, two tran-
scription factors, FOXD3 and OTX2, were found to promote the
transition from naïve to formative pluripotency by coordinating
the silencing of naïve genes and the activation of early post-
implantation epiblast markers9,19,20. Subsequently, FOXD3 and
OTX2 restrict the differentiation of EpiLC into PGCLC and, thus,
the silencing of these TFs is required for in vitro germline
specification9,20. The regulatory function of FOXD3 during these
developmental transitions involves binding to and silencing of
enhancers shared between naïve pluripotent cells and PGCLC9.
Interestingly, during the transition from 2i ESC to EpiLC,
FOXD3-bound enhancers lose TF and co-activator binding as
well as H3K27ac but partly retain H3K4me1. This suggests that
these enhancers do not become fully decommissioned, but tran-
siently display a chromatin state similar, but not identical, to that
of primed enhancers21,22. Enhancer priming typically involves
binding of pioneer TFs and pre-marking by H3K4me1 that can
precede and facilitate subsequent enhancer activation (i.e.
marking by H3K27ac, recruitment of RNA Pol II, production of
eRNAs)23–26. Interestingly, in differentiated macrophages,
enhancers activated upon stimulation rapidly lose H3K27ac and
TF binding, while retaining H3K4me1 for considerably longer. It
was proposed that H3K4me1 persistence could facilitate a faster
and stronger enhancer induction upon restimulation27. It is
currently unknown whether, during development, H3K4me1
persistence once enhancers become decommissioned can simi-
larly facilitate their eventual re-activation21.
H3K4me1 is catalyzed by the SET domains of the histone
methyltransferases MLL3 (KMT2C) and MLL4 (KMT2D), which
are part of the COMPASS Complex28,29. The knockout (KO) of
Mll3/4 or Mll4 alone impairs enhancer activation and results in
differentiation defects in various lineages30–37. However, the
importance of MLL3/4 for enhancer function might be inde-
pendent of H3K4me1 deposition, since Mll3/4 catalytic mutant
ESC (Mll3/4 dCD) in which H3K4me1 was globally lost, only
displayed minor defects in enhancer activation (i.e. H3K27ac,
RNA Pol II and eRNA levels) in comparison to Mll3/4 KO ESC38.
Similarly, work in Drosophila melanogaster showed that, while the
KO of Trr, the homolog of Mll3/4 in flies, was embryonic lethal,
an amino acid substitution in the SET domain of Trr that globally
reduced H3K4me1 did not impair development or viability39. On
the other hand, subsequent work with Mll3/4 dCD ESC showed
that the recruitment of chromatin remodelers40 and the estab-
lishment of long-range chromatin interactions32 required
H3K4me1. Hence, the functional relevance of H3K4me1 for
enhancer function is still under debate41.
Here we perform an extensive transcriptional and epigenetic
characterization of the main stages of PGCLC differentiation to
gain insights into the molecular basis of germline competence.
Comparisons between germline competent EpiLC and non-
competent EpiSC reveal that a notable fraction of PGCLC
enhancers, which tend to be already active in the naïve stage
(i.e. 2i ESC), partly retain H3K4me1 and remain accessible and
responsive to TFs in EpiLC in comparison to EpiSC. Most
importantly, the persistence of H3K4me1 within PGCLC
enhancers seems to contribute to in vitro germline competence,
as the absence of this histone mark reduces PGCLC differentia-
tion efficiency.
Results
Characterization of the PGCLC in vitro differentiation system
by single-cell RNA-seq. To overcome the scarcity and transient
nature of PGCs in vivo, we used an in vitro PGCLC differentia-
tion system10 whereby mouse ESC are differentiated into EpiLC
from which PGCLC can be obtained within heterogeneous
embryoid bodies (EB). In contrast, Epiblast stem cells (EpiSC),
resembling the post-implantation gastrulating epiblast, cannot be
efficiently differentiated into PGCLC and, thus, display limited
germline competence (Fig. 1a)7,10. To better characterize this
in vitro system, we performed single-cell RNA sequencing
(scRNA-seq) across multiple stages of PGCLC differentiation (the
scRNA-seq data can be easily explored with the cloupe file
available through GEO: GSE155088). t-SNE analysis of the
resulting single-cell transcriptomes (Supplementary Data 1)
showed that cells tend to cluster within their corresponding dif-
ferentiation stage (Fig. 1b). However, Day 2 and Day 4 EB showed
cellular heterogeneity and formed distinct subclusters (Fig. 1b, c).
One of these subclusters was identified as PGCLC based on the
high expression of major PGC markers (e.g. Prdm14, Prdm1,
Tfap2c, Dppa3), while the additional subpopulations within d4
EB were annotated based on the expression of cell identity
markers identified by single-cell transcriptional profiling of E8.25
mouse embryos42 (Fig. 1c, Supplementary Fig. 1a, b). Remark-
ably, these subclusters were similar to the extraembryonic tissues
(i.e. extraembryonic ectoderm, extraembryonic mesoderm, and
endothelium) that surround PGCs in the proximo-posterior end
of the mouse embryo following germline specification in vivo.
Furthermore, differential expression analysis between the PGCLC
cluster and the remaining cells of the d2 and d4 EBs (see
Methods) led to the identification of a set of 389 PGCLC genes
(Supplementary Data 2), which included the PGC markers
mentioned above as well as major naïve pluripotency regulators
(e.g. Nanog, Esrrb) (Fig. 1d, e). In agreement with previous
reports10, we found that several PGCLC genes were more highly
expressed in ESC, progressively silenced in EpiLC, and finally
reactivated in PGCLC (Fig. 1d, e, Supplementary Fig. 1c). Despite
the similar expression profile of ESC and PGCLC, major ESC (e.g.
Klf4, Zfp57, Tbx3) and PGC (e.g Prdm1, Dppa3, Dnd1) markers
were specifically expressed in the ESC and PGCLC clusters,
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respectively (Fig. 1e, Supplementary Fig. 1d, Supplementary
Data 2). Furthermore, differential expression analysis between
PGCLC and in vitro pluripotent cell types (i.e. ESC, d2 EpiLC,
and EpiSC) showed that ~25% of the PGCLC genes (100/389)
displayed a PGCLC specific expression pattern (Supplementary
Fig. 1e). Therefore, despite their similarities, 2i ESC and PGCLC
are transcriptionally distinct. Lastly, we also defined gene sets
specific for the three investigated in vitro pluripotent cell types
(i.e. ESC, d2 EpiLC, and EpiSC) by performing differential gene
expression analysis between each cell type and the other two
(Supplementary Data 2).
Germline competent EpiLC are transcriptionally homo-
geneous. Previous work indicates that the acquisition of germline
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competence in day 2 (d2) EpiLC entails the complete dismantling
of the naïve gene expression program5,6, which is then partly re-
activated during PGCLC induction. In agreement with this, all d2
EpiLC clustered together and neither a distinct subpopulation
indicative of a retained naïve pluripotency expression program
nor signs of precocious germline induction could be identified
(Fig. 1b, f; Supplementary Fig. 1f). Congruently, the cell-to-cell
variability in gene expression levels, defined as transcriptional
noise, was significantly lower in d2 EpiLC than in the preceding
or subsequent cellular stages (Fig. 1g). This is in agreement with
the transcriptional homogeneity of the E5.5 epiblast in vivo43,
which bears the lowest transcriptional noise during mouse peri-
implantation development44. Lastly, we analyzed bulk RNA-seq
data generated in Otx2−/−20 and Prdm14−/−14 EpiLC, which
despite displaying increased and decreased germline competence,
respectively, showed normal expression of PGCLC genes (Sup-
plementary Fig. 1g). Therefore, in agreement with the previous
work6, our scRNA-seq analysis indicates that in vitro germline
competence entails a transcriptionally homogeneous stage in
which the gene expression program shared between naïve plur-
ipotency and PGCLC is silenced.
Identification of PGCLC active enhancers. Many PGCLC genes,
especially those active in ESC, are silenced in EpiLC and EpiSC
(Fig. 1d, e, Supplementary Fig. 1c), yet only EpiLC display high
germline competence. Taking previous observations into
account9,45,46, we hypothesized that enhancers involved in the
induction of PGCLC genes might display epigenetic differences
between EpiLC and EpiSC that could explain their distinct
germline competence. To test this hypothesis, we first identified
distal H3K27ac peaks in d6-sorted PGCLC using publically
available data15. In agreement with our previous observations9, a
large fraction of the d6 PGCLC H3K27ac peaks were initially
active in ESC, lost H3K27ac in EpiLC, and became progressively
reactivated in d2 and d6 PGCLC (Supplementary Fig. 2a). Since
most of the d6 PGCLC H3K27ac peaks were also active in ESC,
we then used Capture Hi-C data generated in ESC47 to system-
atically associate these distal peaks to their putative target genes.
Finally, we defined PGCLC enhancers as those distal d6 PGCLC
H3K27ac peaks that could be physically linked to our PGCLC
gene set (Supplementary Data 2). This resulted in 415 PGCLC
enhancers linked to 216 of the 389 PGCLC genes (Fig. 2a).
Furthermore, to compare epigenetic changes between different
enhancer groups, EpiLC and EpiSC enhancers were defined using
similar criteria (Methods; Supplementary Data 3).
To validate our PGCLC enhancer calling strategy, we first
selected three representative enhancers linked to Esrrb, Klf5,
and Lrrc31/Lrrc34, respectively (Fig. 2b, Supplementary Fig. 2b).
These three enhancers were initially active in ESC, got silenced
in EpiLC, and finally became re-activated in PGCLC. Each
enhancer was individually deleted in ESC using CRISPR/Cas9
technology (Supplementary Fig. 2c). The deletion of the
enhancers associated with Lrrc31/Lrrc34 and Klf5 significantly
reduced the expression of the corresponding target genes in
ESC and d4 EB (Supplementary Fig. 2d, e). The Esrrb enhancer
deletion had a moderate effect in ESC and severely diminished
Esrrb expression in d4 EB (Fig. 2c). The moderate effect in ESC
could be explained by the presence of additional ESC-specific
enhancers (Fig. 2b) that might control Esrrb expression in ESC
and compensate for the enhancer deletion48. Similarly, since
some PGCLC genes are associated with multiple and potentially
redundant regulatory elements in PGCLC (i.e. 415 enhancers
linked to 216 PGCLC genes; 1.9 enhancers/gene), we individu-
ally deleted three different enhancers (i.e. E1, E2, and E3)
(Fig. 2d; Supplementary Fig. 2c) previously described as
components of a Prdm14 super-enhancer49. In agreement with
previous work, the E2 deletion strongly reduced Prdm14
expression in ESC, while the deletion of E3 or E1 had
considerably smaller effects (Fig. 2e)49. Upon PGCLC differ-
entiation, the regulatory importance of each enhancer changed
and E1 clearly contributed to Prdm14 expression, especially
during early PGCLC induction (Fig. 2e). These results suggest
that, rather than being components of an ESC super-enhancer,
the E1–E3 elements differentially contribute to Prdm14
expression in either ESC (i.e. E2) or early (d2 EBs) PGCLC
(i.e. E1). Furthermore, in agreement with the role of Prdm14 as
a PGC master regulator50, we found that the individual E1–E3
deletions significantly impaired PGCLC differentiation (Fig. 2f,
Supplementary Fig. 2f). However, for the E2 and E3 enhancer
deletions, we can not exclude that the impaired PGCC
differentiation might be caused, at least partially, by the initial
decrease in Prdm14 expression in ESC, which might compro-
mise naïve pluripotency by increasing the levels of de novo
DNA methyltransferases and, thus, of CpG methylation51–53.
Altogether, the previous deletions support the relevance of the
identified PGCLC enhancers and suggest that some of them
(e.g. Esrrb and Prdm14 E1 enhancers) are particularly relevant
during PGCLC induction, while others might be important in
both ESC and PGCLC.
Partial decommissioning of PGCLC enhancers in EpiLC. To
explore whether PGCLC enhancers display any chromatin dif-
ferences between EpiLC and EpiSC, we generated an extensive set
of ChIP-seq and ATAC-seq data sets in ESC, EpiLC, and EpiSC
(Fig. 3a; Supplementary Fig. 3a). Overall, the most pronounced
changes within PGCLC enhancers were observed for H3K4me1,
Fig. 1 scRNA-seq profiling of the in vitro PGCLC differentiation system. a Schematic representation of the in vitro PGCLC differentiation system.
Embryonic stem cells (ESC) are differentiated into epiblast-like cells (EpiLC). Day 2 (d2) EpiLC are germline competent and can be differentiated into
embryoid bodies (EB) containing primordial germ cell-like cells (PGCLC). In contrast, the progress of EpiLC into epiblast stem cells (EpiSC) restricts
germline competence. The diagram to the far right illustrates the in vivo location of PGCs at the proximal-posterior end of a mouse embryo (ExE:
Extraembryonic Ectoderm; ExM: Extraembryonic Mesoderm, PGC: Primordial germ cells). b t-SNE plot of the scRNA-seq data (n= 2782 cells) generated
across the main stages of the in vitro PGCLC differentiation protocol. c t-SNE plot based on the scRNA-seq data generated in d4 EB (n= 368 cells).
K-means clustering of d4 EB identified four clusters resembling the transcriptomes of PGCs and their main surrounding tissues in vivo: ExE, ExM, and
Endothelial cells. d Gene expression summary for the different gene sets defined using the scRNA-seq data (see Methods). The number of genes in each
set is indicated below and the size of a dot represents the average expression of all genes within a gene set for the indicated cellular stages (UMI: unique
molecular identifier). e Heatmap showing the expression of selected genes from the gene sets shown to the left (i.e. ESC, EpiLC, EpiSC, and PGCLC gene
sets) within individual cells belonging to the indicated cellular stages. The expression values are displayed as UMI counts. f t-SNE plot for the d2 EpiLC
scRNA-seq data alone (n= 289 cells). g Violin plots showing transcriptional noise (defined as cell-to-cell transcript variation for the 500 most variable
genes) for ESC, EpiLC, and EpiSC. Lower transcriptional noise indicates higher transcriptional similarity between the cells belonging to a particular stage. All
cellular stages shown were compared to d2 EpiLC using two-sided Wilcoxon tests (*p-value < 2.2 × 10−16). The horizontal line in the boxplots indicates the
median, the box indicates the first and third quartiles and the whiskers indicate ± 1.5 × interquartile range.
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Fig. 2 Identification and functional assessment of PGCLC enhancers. a H3K27ac dynamics for EpiLC, EpiSC, and PGCLC enhancers during PGCLC
differentiation (see Methods for the definition of enhancer sets). Enhancers within each set were ordered according to the H3K27ac levels in the
corresponding cell type. RPGC: reads per genomic content. b ATAC-seq, H3K27ac, and CpG methylation dynamics during PGCLC differentiation for
the Esrrb locus. A PGCLC enhancer physically linked to the Esrrb according to capture Hi-C data47 is highlighted in gray. H3K27ac peaks found only in
ESC and representing putative ESC-specific enhancers are highlighted in light blue. The blue rectangle denotes the generated enhancer deletion. c Esrrb
expression levels were measured by RT-qPCR in d4 EB differentiated from WT ESC and the two ESC clonal lines with the Esrrb enhancer deletion
shown in (b). The expression values were normalized to two housekeeping genes (Eef1a1 and Hprt). The bar plots show the mean expression ± SD
from 6 measurements (two clonal lines × three technical replicates shown as circles). d H3K27ac and CpG methylation dynamics during PGCLC
differentiation for three PGCLC enhancers (E1–E3) found within the Prdm14 locus. The blue rectangles denote the generated enhancer deletions. The
E1-E2 enhancers are physically linked to Prdm14 in ESC according to capture Hi-C data47. RPGC: reads per genomic content. e Prdm14 expression levels
were measured by RT-qPCR in d4 EB differentiated from WT ESC and ESC with the indicated Prdm14 enhancer deletions (two clonal lines for each
deletion). The expression values were normalized to two housekeeping genes (Eef1a1 and Hprt). The bar plots show the mean expression ± SD from 6
measurements (two clonal lines x three technical replicates shown as circles). f WT ESC and ESC lines with the indicated Prdm14 enhancer deletions
were differentiated into PGCLC. PGCLC were measured as CD15+CD61+ cells within d4 EB. Each PGCLC quantification is shown as means ± SD from
biological duplicates and two different clonal lines for each enhancer deletion (n= 2 × 2). The p-values were calculated using two-sided Wilcoxon
tests comparing cells with enhancer deletions to WT cells.
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which was higher in EpiLC, and H3K9me3 and mCpG, which
were increased in EpiSC (Fig. 3a, b). These differences were not
observed for other enhancer groups (e.g. EpiSC enhancers),
suggesting that they were not due to technical reasons or global
epigenomic differences between EpiLC and EpiSC (Fig. 3a).
Moreover, when analyzing the transcription start sites (TSS) of
the PGCLC genes we found that, although H3K4me1 was higher
in EpiLC than in EpiSC, its overall levels were low compared to
PGCLC enhancers (Fig. 3a). Similarly, constitutive hetero-
chromatin marks (e.g. H3K9me3, mCpG) around TSS increased
in EpiSC, but their levels were lower than within PGCLC
enhancers. Other chromatin features typically found at promoter
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regions (e.g. H3K4me2/3, high chromatin accessibility) were
similar around PGCLC TSS in EpiLC and EpiSC (Fig. 3a).
Therefore, subsequent analyses were focused on PGCLC enhan-
cers rather than promoters.
To identify PGCLC enhancers showing consistent differences
between EpiLC and EpiSC, we focused on H3K4me1, which is
widely considered as an enhancer mark54. We generated two
additional H3K4me1 ChIP-seq replicates in EpiLC and EpiSC
(including data from a different ESC strain i.e. R1) and classified
PGCLC enhancers in two groups: Group I: PGCLC enhancers
showing an EpiLC/EpiSC H3K4me1 ratio higher than 1.2-fold in
at least two replicates Group II: all other PGCLC enhancers
showing EpiLC/EpiSC H3K4me1 ratios lower than 1.2-fold.
Based on this classification, 71% of the PGCLC enhancers were
assigned to Group I and, thus, showed higher H3K4me1 levels in
EpiLC than in EpiSC in at least two replicates (71% Group I; 29%
Group II) (Fig. 3c, d; Supplementary Fig. 3b, c). The Group I
PGCLC enhancers also retained more H3K27ac in EpiLC, while
the differences in H3K4me2 and chromatin accessibility, as
measured by ATAC-seq, were rather moderate (Supplementary
Fig. 3d). In contrast, the Group I enhancers displayed lower
mCpG and H3K9me3 levels in EpiLC than in EpiSC, while these
differences were considerably less obvious for the Group II
enhancers (Fig. 3d, e, Supplementary Fig. 3e). Notably, previous
work showed that germline genes and enhancers are repressed by
the H3K9 methyltransferase EHMT2 during mouse post-
implantation development45, suggesting that Group I enhancers
get progressively silenced as ESC differentiate into EpiLC and
EpiSC. Furthermore, H3K4me1 and mCpG were inversely
correlated across Group I PGCLC enhancers, particularly in
EpiLC (Fig. 3f). This negative correlation was also investigated by
performing H3K4me1 ChIP in EpiLC followed by bisulfite
sequencing of two representative Group I PGCLC enhancers
(i.e. Esrrb and Lrrc31/Lrrc34 enhancers) (Fig. 3g). In comparison
to the input genomic DNA, the H3K4me1-enriched DNA showed
lower mCpG levels at the two analyzed enhancers (Fig. 3g),
further supporting the antagonism of CpG methylation and
H3K4 methylation55,56.
In summary, a subset of the PGCLC enhancers shows partial
retention of H3K4me1 and lower levels of heterochromatic marks
(i.e. mCpG, H3K9me3) in EpiLC compared to EpiSC (Fig. 3d, e).
These enhancers tend to be initially active in ESC but lose
H3K27ac and TF/coactivator binding (indirectly measured by
ATAC-seq) already in EpiLC (Supplementary Fig. 3d). Therefore,
our data suggest that a significant fraction of PGCLC enhancers
are not fully decommissioned in EpiLC, which we hypothesize
could facilitate their re-activation in PGCLC and, thus, contribute
to germline competence.
Impaired decommissioning of PGCLC enhancers in Otx2
deficient cells. The deletion of Otx2 increases and prolongs
germline competence in EpiLC20. Hence, to further explore the
relationship between the chromatin features of PGCLC enhancers
and germline competence, we analyzed Otx2−/− cells57. Firstly,
we confirmed the extended germline competence of Otx2−/−
cells, which can be robustly differentiated into PGCLC after
keeping them for up to seven days in EpiSC culture conditions
(Fig. 4a, Supplementary Fig. 4a). ChIP-seq experiments revealed
that the increased germline competence of Otx2−/− cells was
correlated with the retention of H3K4me1, H3K4me2, and
H3K27ac in PGCLC enhancers, particularly within those dis-
playing higher levels of H3K4me1 in WT EpiLC (i.e. Group I
enhancers) (Fig. 4b, c, Supplementary Fig. 4b). Moreover,
H3K4me1/2 levels were higher in Otx2−/− ESC than in WT ESC
in some but not all of the investigated Group I enhancers (Sup-
plementary Fig. 4c). Nevertheless, the correlation between
germline competence and H3K4me1 levels within PGCLC
enhancers was not perfect, since Otx2−/− d4 EpiSC displayed
higher germline competence than WT EpiLC, yet slightly lower
H3K4me1 levels within Group I enhancers (Fig. 4c). Therefore, in
addition to H3K4me1, other chromatin features within PGCLC
enhancers might also contribute to the extended germline com-
petence of Otx2−/− cells. In agreement with this possibility,
Group I enhancers showed slightly higher H3K4me2 in Otx2−/−
d4 EpiSC than in WT EpiLC (Fig. 4c). Furthermore, genome-
wide as well as detailed analysis of representative enhancers (i.e.
Esrrb and Prdm1 enhancers) showed that the increased compe-
tence of Otx2−/− EpiLC and d4 EpiSC was also reflected in
reduced CpG methylation levels within Group I PGCLC enhan-
cers (Fig. 4d, Supplementary Fig. 4d). Overall, as the PGCLC
genes get properly silenced in Otx2−/− EpiLC (Supplementary
Fig. 1g), these results suggest that the extended germline com-
petence of Otx2−/− cells could be linked to the impaired and
delayed decommissioning of a subset of PGCLC enhancers.
Partially decommissioned PGCLC enhancers are accessible and
responsive to transcriptional activators in EpiLC. To investigate
whether the partial decommissioning of PGCLC enhancers in
EpiLC compared to EpiSC could have any functional con-
sequences, we evaluated the accessibility of these enhancers to
major PGCLC transcriptional activators. To this end, we gener-
ated clonal ESC lines in which HA-tagged PRDM14 or NANOG
could be overexpressed upon the addition of Doxycycline (Dox)
(Supplementary Fig. 4e, f). In agreement with previous reports,
the overexpression of either PRDM14 or NANOG upon differ-
entiation of EpiLC into PGCLC yielded a high percentage of
Fig. 3 Chromatin features of PGCLC enhancers in ESC, EpiLC, and EpiSC. a Chromatin marks were measured in ESC, EpiLC, and EpiSC for the indicated
enhancers and the TSS of the PGCLC genes. Quantifications were performed by measuring average signals within 1 kb of the enhancers or TSS (RPGC:
Reads per genomic content). b The magnitude of the differences in chromatin marks between EpiLC and EpiSC within PGCLC enhancers (n= 415) was
determined as the effect sizes from paired two-sided Wilcoxon tests. The bar plots show the effect size and the error bars represent the confidence
intervals (0.95). c Three H3K4me1 ChIP-seq replicates were generated in EpiLC and EpiSC, respectively. For each replicate, the average H3K4me1 signal
within 1 kb of each PGCLC enhancer was calculated. PGCLC enhancers showing EpiLC/EpiSC ratios >1.2-fold were assigned to the ‘EpiLC>EpiSC’ category.
PGCLC enhancers assigned to the ‘EpiLC>EpiSC’ category in at least two replicates were defined as Group I. All other enhancers were assigned to Group II.
d H3K4me1 levels (first replicate) for Group I and II PGCLC enhancers in EpiLC and EpiSC. P-values were calculated using paired two-sided Wilcoxon tests.
e H3K9me3 and CpG methylation levels for Group I and II PGCLC enhancers in EpiLC and EpiSC. P-values were calculated using paired two-sided Wilcoxon
tests. The scales for H3K9me3 and CpG methylation data are shown as RPGC and % of methylated CpGs, respectively. f Correlation plots between CpG
methylation and H3K4me1 at Group I PGCLC enhancers. For each enhancer, the average CpG methylation and H3K4me1 levels (first ChIP-seq replicate)
were calculated for two 500 bp bins up- and downstream of each enhancer, and spearman correlations (ρ) were determined. g Bisulfite sequencing
analysis of the PGCLC enhancers associated with Esrrb and Lrrc31/34 using as templates input DNA, H3K4me1 ChIP DNA, and H3K4me2 ChIP DNA
generated in EpiLC. The columns correspond to individual CpGs within each enhancer that are unmethylated (blue), methylated (red), or not sequenced
(gray). At least 10 alleles were analyzed for each template DNA (rows). In (e) and (f) the CpG methylation data were obtained from Zylicz et al. 201545.
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PGCLC in the absence of growth factors (Fig. 4e, Supplementary
Fig. 4g)12,58. In contrast, the overexpression of PRDM14 or
NANOG upon differentiation from EpiSC resulted in con-
siderably less PGCLC (Fig. 4e, Supplementary Fig. 4g). To assess
whether PGCLC enhancers were differentially accessible to these
TFs in EpiLC and EpiSC, we performed ChIP-seq experiments
after a short induction of HA-tagged PRDM14 or NANOG in
both cell types. Importantly, PGCLC enhancers, especially those
belonging to Group I, were considerably more bound by
PRDM14-HA and NANOG-HA in EpiLC than in EpiSC (Fig. 4f).
Furthermore, NANOG-HA binding to the PGCLC enhancers
resulted in increased H3K27ac and H3K4me2 levels in EpiLC but
not in EpiSC, particularly within Group I enhancers (Fig. 4g, h,
Supplementary Fig. 4h). Altogether, these results indicate that
PGCLC enhancers, especially those belonging to Group I, are
both accessible and responsive to transcriptional activators in
EpiLC but not in EpiSC.
Increased decommissioning of PGCLC enhancers in the
absence of H3K4me1. Our data suggest that a significant fraction
of PGCLC enhancers display permissive chromatin features in
EpiLC that might contribute to their increased germline compe-
tence compared to EpiSC. These permissive features could be
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EpiLC, as this histone mark could (i) protect PGCLC enhancers
from mCpG and H3K9me2/356,59–63 and/or (ii) facilitate the
recruitment of chromatin remodeling complexes40. To directly
assess the importance of H3K4me1 for germline competence and
PGCLC specification, we used mESC catalytically deficient for
MLL3 and MLL4 (dCD and dCT ESC lines; Fig. 5a)38. Previous
work showed that in dCD ESC, active enhancers show a moderate
reduction in H3K27ac, while gene expression, eRNA levels, and
the binding of MLL3/4 and their associated complexes are not
affected, indicating that H3K4me1 is largely dispensable for the
maintenance of enhancer activity (Supplementary Fig. 5a)38,39.
Additional characterization of dCD and dCT cell lines revealed
that, upon differentiation, the major reductions in H3K4me1 and
H3K4me2 that PGCLC enhancers already displayed in ESC
became further exacerbated in EpiLC and EpiSC (Fig. 5b, c,
Supplementary Fig. 5b–d). Moreover, H3K27ac levels within
PGCLC enhancers were also reduced in dCD/dCT cells compared
to their WT counterparts, although such differences were not as
pronounced as for H3K4me1 (Fig. 5b, Supplementary Fig. 5b, d).
Similarly, other enhancer groups (i.e. EpiLC and EpiSC enhan-
cers) also displayed strong H3K4me1/2 losses and milder
H3K27ac reductions in dCD cells (Fig. 5c, Supplementary Fig. 5d,
g). In contrast, the levels of the previous active histone mod-
ifications were rather similar around the TSS of PGCLC genes,
with H3K4me1 even showing a slight increase in dCD cells
(Supplementary Fig. 5d). In agreement with the protective role of
H3K4me1/2 against CpG methylation56,60, mCpG levels within
PGCLC enhancers were generally elevated in dCD ESC64, while
in dCD EpiLC the increased methylation was evident among
some Group I enhancers (Fig. 5d, Supplementary Fig. 5e, f). Next,
to evaluate the potential functional consequences of the previous
epigenetic changes, we generated RNA-seq data in WT and
dCD ESC, EpiLC, and EpiSC. In agreement with previous work in
ESC indicating that H3K4me1 is dispensable for enhancer
function38,39, the genes associated with PGCLC, EpiLC, and
EpiSC enhancers showed rather minor expression differences
between WT and dCD cells in the three investigated cell types
(Fig. 5e, Supplementary Fig. 5h, i, Supplementary Data 4).
Overall, our analyses indicate that the decommissioning of a
subset of PGCLC enhancers gets exacerbated in dCD EpiLC
compared to their WT counterparts, resulting in a chromatin
state similar to the one observed in WT EpiSC (i.e. lower
H3K4me1 and higher mCpG; Fig. 3). However, these epigenetic
changes do not result in major gene expression changes in any of
the investigated in vitro pluripotent cell types.
H3K4me1 is necessary for in vitro germline competence. To
address whether the increased decommissioning of PGCLC
enhancers observed in dCD/dCT EpiLC could compromise their
germline competence, these MLL3/4 catalytic mutant cell lines
were differentiated into PGCLC. Chiefly, both dCD and dCT cells
showed a significant reduction in their PGCLC differentiation
capacity (Fig. 6a, Supplementary Fig. 6a). In agreement with
MLL3 and MLL4 being functionally redundant65, such PGCLC
differentiation defects were not observed when using cells that
were catalytic mutant for MLL4 but not MLL3 (i.e. 4CT cells)
(Fig. 5a, Fig. 6a). Furthermore, the compromised PGCLC dif-
ferentiation of the dCD cells was still observed at a later time
point (day 6, Supplementary Fig. 6b), indicating that the observed
defects are not simply explained by a delay in PGCLC
specification.
To gain molecular insights into the compromised PGCLC
differentiation capacity of dCD cells, we performed scRNA-seq
analyses of WT (1416 cells) and dCD (1699 cells) d4 EBs
(Supplementary Data 5). UMAP (Uniform Manifold Approx-
imation and Projection for Dimension Reduction) analysis of the
resulting single-cell transcriptomes confirmed the presence within
d4 EBs of subclusters resembling the main cell populations (i.e.
PGCLC, ExEctorderm-like, ExMesoderm-like) that characterize
the proximo-posterior end of the mouse embryo following
germline specification (Fig. 6b). In addition, we also identified
additional subclusters (i.e. ExEndoderm/Gut-like, 2-cell-like;
Fig. 6b) that were not observed in the previous scRNA-seq
analyses (Fig. 1, Supplementary Fig. 1), probably due to the lower
number of d4 EB cells sequenced in those initial experiments.
Most importantly, the PGCLC cluster consisted mostly of
WT cells (162 WT cells (11.4% of all cells in WT d4 EBs) vs 8
dCD cells (0.5% of all cells in dCD d4 EB); Fig. 6c, d), suggesting
that the defective PGCLC differentiation of dCD cells might be
even more pronounced than our experiments using FACS and
cell surface markers indicate (Fig. 6a). Moreover, while the
transcriptomes of some extraembryonic-like cell types were
similar between WT and dCD cells (e.g. Ex-Endoderm/Gut-like,
Endothelial-like), many dCD cells were located in clusters with
poorly defined identity that did not show differential expression
of specific markers (Fig. 6b, Supplementary Fig. 6c). These
undefined clusters were transcriptionally more heterogeneous
than the remaining clusters found within the d4 EBs (Supple-
mentary Fig. 6d). Interestingly, we noticed that within some of
the non-PGCLC clusters there were cells showing high expression
of PGCLC genes (Supplementary Fig. 6e) and, thus, a cellular
identity somehow similar to PGCLC. Therefore, to further
explore the PGCLC differentiation defects of the dCD cells we
used an alternative approach to identify all cells within the WT
and dCD d4 EBs that express major PGC markers (i.e. Prdm1 or
Dppa3) but not naïve pluripotency ones (i.e. Klf4). Although the
Fig. 4 In vitro germline competence is correlated with the partial decommissioning of PGCLC enhancers. a E14 WT and Otx2−/− ESC were differentiated
into d2 EpiLC, d4 EpiSC or d8 EpiSC, which were then differentiated into PGCLC. PGCLC were quantified as the percentage of CD15+CD61+ cells within d4
EB. Bar plots: mean percentage of PGCLC ± SD from at least two biological replicates. b Average levels of chromatin marks measured in WT and Otx2−/−
d2 EpiLC within 1 kb of the indicated enhancers. c H3K4me1 and H3K4me2 levels for Group I and II PGCLC enhancers in d2 EpiLC, d4 EpiSC, and d8 EpiSC
differentiated from E14 WT or Otx2−/− ESC. P-values were calculated using paired two-sided Wilcoxon tests. Scales: RPGC. d CpG methylation for Group I
and II PGCLC enhancers in d2 EpiLC differentiated from WT or Otx2−/− ESC. P-values were calculated using paired two-sided Wilcoxon tests. Scale:
percentage of methylated CpGs. e WT ESC and ESC lines enabling overexpression of NANOG-HA (blue) or PRMD14-HA (red) were differentiated into d2
EpiLC and EpiSC. D2 EpiLC and EpiSC were differentiated into PGCLC with (+Dox) or without (ctrl) Doxycycline and in the absence of growth factors. As a
positive control, WT d2 EpiLC and EpiSC were differentiated with growth factors (WT+GF). Bar plots: mean percentage of PGCLC (CD15+CD61+ cells) in
d4 EB ± SD from two biological replicates. f PRDM14-HA and NANOG-HA ChIP-seq signals in EpiLC and EpiSC in which PRDM14-HA or NANOG-HA were
overexpressed. P-values were calculated using paired two-sided Wilcoxon tests. Scales: RPGC. g ESC enabling inducible overexpression of NANOG-HA
were differentiated into d2 EpiLC and EpiSC. Cells were left untreated or treated with Doxycycline and H3K27ac ChIP-seq experiments were performed.
P-values were calculated using paired two-sided Wilcoxon tests. Scales: RPGC. h NANOG-HA (two replicates in EpiSC), H3K27ac, and H3K4me2 signals in
untreated (-Dox) and Dox-treated (i.e. NANOG-HA overexpression) EpiLC and EpiSC are shown for the Klf5 and Esrrb loci. Deleted PGCLC enhancers are
highlighted in blue and other PGCLC enhancers in gray. In (b–c), the H3K4me1 data for WT d2 EpiLC and d8 EpiSC corresponds to the second replicates
from Fig. 3c.
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Fig. 5 H3K4me1 is dispensable for enhancer-dependent gene expression in in vitro pluripotent cells. a dCD cells express catalytic mutant MLL3 and
MLL4 proteins without histone methyltransferase activity but capable of binding to their target sites and interacting with other proteins as part of the
COMPASS complex. The differentMll3/4 catalytic mutants used in this study are shown to the right. b H3K4me1 and H3K27ac levels for the Group I and II
PGCLC enhancers in R1 WT and MLL3/4 catalytic mutant ESC lines as well as upon their differentiation into d2 EpiLC and EpiSC. P-values were calculated
using paired two-sided Wilcoxon tests. The H3K4me1 ChIP-seq data shown for WT d2 EpiLC and EpiSC are the same ones used in Fig. 3c as a third
replicate. Scales: RPGC. c H3K4me1, H3K4me2, and H3K27ac profiles in both WT and MLL3/4 catalytic mutant cells (ESC, EpiLC, and EpiSC) around
representative PGCLC (Esrrb), EpiLC (Grhl2), and EpiSC (Wnt3) genes and their associated enhancers. d Percentage of CpG methylation for the Group I and
II PGCLC enhancers in WT and dCD ESC as well as upon their differentiation into d2 EpiLC. P-values were calculated using paired two-sided Wilcoxon
tests. The WGBS data in 2i ESC was obtained from Skvortsova et al. 201964. Scale: percentage of methylated CpGs. e Expression (as measured by RNA-
seq) of the genes associated with the PGCLC, EpiLC, and EpiSC enhancers in WT (gray) and dCD (red) ESC cells as well as upon their differentiation into
EpiLC and EpiSC. The RNA-seq data in ESC was obtained from Dorighi et al. 201738 and the experiments in d2 EpiLC and EpiSC were performed in
duplicates. The horizontal line in the boxplots indicates the median, the box indicates the first and third quartiles and the whiskers
indicate ± 1.5 × interquartile range. TPM transcripts per million.
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Fig. 6 H3K4me1 is important for the proper induction of PGCLC and their associated gene expression program. a WT ESC and ESC lines with MLL3/4
amino acid substitutions were differentiated into PGCLC. PGCLC were quantified as the percentage of CD15+CD61+ cells within d4 EB. Barplots: mean
percentage of PGCLC ± SD from at least four biological replicates. P-values were calculated using two-sided Wilcoxon tests. b UMAP plot showing cell
clusters identified within WT and dCD d4 EB according to scRNA-seq data. Cluster identity was determined by differential expression analysis between
clusters and using specific tissue markers found in E8.25 mouse embryos42. c Same UMAP plot as in b, with WT and dCD cells represented by red and blue
dots, respectively. d Percentage of WT and dCD cells found within the PGCLC cluster shown in c. e Cluster distribution of WT (left) and dCD (right)
Prdm1orDppa3+/Klf4- cells. f Transcript levels of all PGCLC genes in WT or dCD Prdm1orDppa3+/Klf4- cells located within the indicated d4 EB clusters.
Dots represent cells and the dashed line shows the mean transcript level of the PGCLC genes for all WT and dCD cells except those within the PGCLC
cluster. g Expression of the PGCLC genes linked (n= 216) or not (n= 170) to at least one PGCLC enhancer within WT and dCD Prdm1orDppa3+ /Klf4-
cells. P-values were calculated using paired two-sided student t-tests. The horizontal lines in the boxplots indicate the median, the boxes indicate the first
and third quartiles, and the whiskers the ± 1.5 × interquartile range. h R1 WT, Otx2−/−, dCD, and dCD Otx2−/− ESC were differentiated into PGCLC. PGCLC
were quantified as the proportion of CD15+CD61+ cells within d4 EB. dCD Otx2−/− differentiations were performed in biological triplicates using two
different clonal lines (n= 3 × 2). Other PGCLC measurements were performed in biological triplicates. Barplots: mean percentage of PGCLC ± SD. P-values
were calculated using two-sided Wilcoxon tests. i Percentage of CpG methylation for Group I and II PGCLC enhancers in R1 Otx2−/− and dCD Otx2−/− d2
EpiLC. P-values were calculated using paired two-sided Wilcoxon tests. Scales: percentage of methylated CpGs.
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overall abundance of these Prdm1orDppa3+ /Klf4- cells was
similar in WT and dCD EBs, their distribution among the
different cell clusters was quite different. Namely, the
vast majority of WT Prdm1orDppa3+ /Klf4- cells were found
within the PGCLC cluster (91%), while many dCD cells were
part of the undefined subclusters (61%) (Fig. 6e), suggesting
important transcriptional differences between WT and dCD
Prdm1orDppa3+ /Klf4- cells (Fig. 6f). Congruently, the expres-
sion of the PGCLC genes associated with PGCLC enhancers (e.g.
Tfap2c, Prdm14, Utf1, Esrrb) was significantly reduced in dCD
Prdm1orDppa3+ /Klf4- cells in comparison to their WT counter-
parts, while smaller differences were observed for the PGCLC
genes without associated enhancers (Fig. 6g, Supplementary
Fig. 6f). Overall, our scRNA-seq analyses suggest that the
induction of the PGCLC genes, particularly of those linked to
PGCLC enhancers, is reduced but not fully abrogated in the dCD
cells. Consequently, many dCD cells display a poorly defined
identity in which the PGCLC expression program is only partially
established.
Finally, to further assess the importance of H3K4me1 for
PGCLC induction, we investigated whether the extended germ-
line competence of Otx2−/− EpiLC could be also attributed, at
least partly, to the retention of H3K4me1 and the impaired
decommissioning of PGCLC enhancers (Fig. 4). To this end, we
deleted Otx2 in dCD ESC (i.e. dCD Otx2−/−) as well as in their
parental WT ESC (i.e. R1 Otx2−/−) (Supplementary Fig. 6g) and
differentiated them into PGCLC. As expected, the deletion of
Otx2 in the R1 ESC resulted in increased germline competence
(Fig. 6h), although not as pronounced as in E14 ESC (Fig. 4a)20,
which could be attributed to the variable germline competence
observed among different ESC lines10. Most importantly, both
dCD and dCD Otx2−/− EpiLC showed a strong and similar
reduction in their PGCLC differentiation capacity (Fig. 6h).
Furthermore, genome-wide and locus-specific analyses of mCpG
levels revealed that Group I PGCLC enhancers were considerably
more methylated in dCD Otx2−/− EpiLC than in Otx2−/− EpiLC
(Fig. 6i, Supplementary Fig. 6h).
Altogether, our data strongly suggest that H3K4me1 is
important for in vitro germline competence and proper PGCLC
induction. Although we cannot rule out that gene expression and
epigenetic changes in ESC and/or extraembryonic-like cell types66
might also contribute to the PGCLC differentiation defects
observed in dCD/dCT cells, our data suggests that the persistence
of H3K4me1 within the PGCLC enhancers might facilitate their
reactivation during PGCLC induction.
PGCLC enhancers get heterogeneously decommissioned in
formative epiblast cells in vivo. Overall, our work using the
PGCLC in vitro differentiation system suggests that germline
competence entails the persistence of permissive chromatin fea-
tures within a significant fraction of PGCLC enhancers. To
evaluate whether this is also true in vivo, we took advantage of
several epigenomic datasets recently generated from mouse
embryos67. Firstly, analysis of DNAse I data obtained in E9.5 and
E10.5 PGC showed that our in vitro defined PGCLC enhancers
are highly accessible in vivo (Fig. 7a). Next, to evaluate the
dynamics of PGCLC enhancer decommissioning, we analyzed
genome-wide CpG methylation data from mouse epiblasts68. In
agreement with our in vitro observations, PGCLC enhancers
showing incomplete decommissioning in EpiLC (i.e. Group I
enhancers) displayed lower CpG methylation levels in germline
competent E5.5 epiblast cells than in the E6.5 epiblast (Fig. 7b), in
which germline competence is already reduced4.
Previous single-cell CpG methylation analyses revealed that,
during mouse peri-implantation stages, the formative epiblast is
particularly heterogeneous, especially within enhancers69. There-
fore, we hypothesize that the lower CpG methylation levels
observed for some PGCLC enhancers in the E5.5 epiblast in
comparison to the E6.5 epiblast could be the result of the
increased cell-to-cell variation. To evaluate this idea, we analyzed
single-cell data in which DNA methylation and gene expression
were measured for the same cells across different epiblast stages
(i.e. E4.5, E5.5, and E6.5)43. Firstly, we measured mCpG
heterogeneity by comparing the methylation status of individual
CpGs within PGCLC enhancers70 (Fig. 7c). This analysis revealed
that the formative epiblast (E5.5) displayed the highest variation
in mCpG, while in the primed epiblast (E6.5) the PGCLC
enhancers were more homogeneously methylated (Fig. 7d).
Interestingly, when comparing different enhancer sets across
epiblast stages, the highest epigenetic heterogeneity (~30 %) was
observed for the Group I PGCLC enhancers in the E5.5 epiblast
(Fig. 7e). As the CpG coverage for the Group I PGCLC enhancers
was similar across epiblast stages, the previous differences in
mCpG heterogeneity are unlikely to be caused by technical
reasons (Supplementary Fig. 7a). Lastly, we compared mCpG
levels within Group I PGCLC enhancers and the expression of
their associated genes across the profiled epiblast cells (Fig. 7f).
Similar to what we observed for EpiLC and EpiSC, the PGCLC
genes associated with the Group I enhancers display low and
similar expression in E5.5 and E6.5 epiblast cells despite the
differences in CpG methylation.
Overall, the previous data support that PGCLC enhancers are
also partially decommissioned in the formative epiblast and
indicate that such partial decommissioning could indeed
reflect epigenetic heterogeneity. Nevertheless, the relevance of
the partial decommissioning and epigenetic heterogeneity of
PGCLC enhancers for germline competence in vivo remains to be
demonstrated.
Discussion
Direct evidences supporting the functional relevance of H3K4me1
are scarce, partly due to the difficulties in separating the enzymatic
and non-enzymatic functions of histone methyltransferases71.
This limitation was recently overcome by establishing Mll3/4
catalytic mutant ESC lines in which H3K4me1 is lost from
enhancers38. Under self-renewing conditions, the loss of
H3K4me1 partly reduced H3K27ac but did not affect transcription
from either enhancers or gene promoters, suggesting that
H3K4me1 is dispensable for the maintenance of enhancer
activity38. Similarly, H3K4me1 was not required for de novo
enhancer activation (i.e. without the prior presence of H3K4me1)
upon somatic differentiation of ESC (Fig. 5)66. However, it is still
unclear whether H3K4me1 is important for the activation of
primed enhancers already pre-marked with this histone
modification25,31. In the case of in vitro germline competence,
here we report that a subset of PGCLC enhancers gets partly
decommissioned in EpiLC and retains permissive chromatin fea-
tures, including H3K4me1, already present in a preceding active
state (i.e. in 2i ESC) (Fig. 7g). This resembles the so-called latent
enhancers previously described in differentiated macrophages, in
which, following an initial round of activation and silencing, the
persistence of H3K4me1 was proposed to facilitate subsequent
enhancer induction upon restimulation27. The mechanisms
involved in the persistence of H3K4me1 and other permissive
chromatin features are still unknown, although we can envision at
least two non-mutually exclusive possibilities: (i) a passive
mechanism whereby MLL3/4 binding to PGCLC enhancers is
already lost in EpiLC, but H3K4me1 can still be transiently
retained due to the slow dynamics of H3K4 demethylation72,73;
(ii) an active maintenance mechanism similar to the one reported
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for enhancer priming24,25, whereby the binding of certain TFs
might enable the persistent recruitment of MLL3/4 and the
retention of H3K4me1 within PGCLC enhancers. Since PGCLC
enhancers display low and similar ATAC-seq signals in EpiLC and
EpiSC (Fig. 3), this would argue in favor of passive mechanisms
rather than active retention of TFs and co-activators (e.g. MLL3/4)
in EpiLC.
Drosophila melanogaster embryos expressing catalytic deficient
Trr, the homolog of mammalian Mll3/4, develop normally, thus
arguing against a major role for H3K4me1 in enhancer
function39. In contrast, the loss of MLL3/4 catalytic activities in
mouse embryos resulted in early embryonic lethality (~E8.5)66,
suggesting that H3K4me1 is functionally relevant during mam-
malian embryogenesis. It is important to consider that, in com-
parison to mammalian cells, the D. melanogaster genome
is largely devoid (<0.03%) of CpG methylation throughout its
entire life cycle74. Previous studies have extensively documented
the protective role of H3K4me1/2 against mCpG and
heterochromatinization56,59–63. Congruently, we showed that
H3K4me1 and mCpG levels within PGCLC enhancers are
negatively correlated and that H3K4me1-deficient cells displayed
increased mCpG levels within Group I PGCLC enhancers.
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Therefore, although the importance of mCpG for enhancer
activity is still debated75–77, it is tempting to speculate that the
lack of DNA methylation in flies renders them less sensitive to
H3K4me1 loss. Nevertheless, Trr catalytic mutant fly embryos
displayed aberrant phenotypes under stress conditions, suggesting
that H3K4me1 might help to fine-tune enhancer activity under
suboptimal conditions. Similarly, we found that the induction of
PGCLC genes linked to enhancers was reduced in dCD cells,
although the magnitude of the observed gene expression changes
was moderate (Fig. 6g). Therefore, we propose that H3K4me1
might facilitate, rather than being essential for, enhancer (re)
activation and the robust induction of developmental gene
expression programs (Fig. 7g). This H3K4me1 facilitator role
might involve not only protection from DNA methylation and
heterochromatinization but also increased accessibility and
responsiveness to transcriptional activators (Fig. 4)40 as well as
physical proximity between genes and enhancers32. Future work
in additional species and cellular transitions will establish the
relevance and prevalence of H3K4me1 function within enhancers.
Finally, our work highlights the diverse mechanisms whereby
the epigenetic status of enhancers can contribute to developmental
competence. For instance, a subset of early brain enhancers dis-
plays a poised state in ESC (i.e. H3K4me1+H3K27me3) that
might facilitate their activation upon neural differentiation78,
while in endodermal progenitors the binding of pioneer TFs and
the consequent priming of relevant enhancers by H3K4me1 might
facilitate their activation during subsequent differentiation24,25.
Moreover, recent work based on chromatin accessibility or multi-
omic profiling indicates that the commitment towards certain cell
lineages involves the activation of already accessible enhancers,
while in other cases this can occur through de novo enhancer
activation43,79. Future work will elucidate the prevalence and
regulatory mechanisms by which the chromatin state of enhancers
can contribute to cellular competence and the robust deployment
of developmental gene expression programs. In this regard, it
would be important to evaluate whether, as reported here for
PGCLC induction, the partial decommissioning of enhancers can
be involved in their subsequent reactivation and, thus, in the
induction of gene expression programs in other developmental
contexts. Similar mechanisms might be also important in other
physiological27 and pathological80,81 contexts in which a pre-
viously used but already dismantled gene expression program gets
re-activated.
Methods
WT and transgenic ESC lines. Two different male mouse ESC lines (i.e. E14Tg2a
and R1) were used as indicated for each particular experiment. The Mll3/4 dCD,
Mll3/4 dCT, and Mll4 CT ESC lines were derived from WT R1 ESC as described
in38. The E14 Otx2−/− ESC line57,82 and its parental E14Tg2a ESC were kindly
provided by Christa Bücker. Other transgenic ESC lines generated in this study are
more extensively described in the following sections and are derived from
E14Tg2a ESC.
Cell culture and differentiation protocols. All ESC lines were cultured under
serum+LIF conditions both for regular maintenance and CRISPR/Cas9 genome
editing experiments. More specifically, ESC were cultured on gelatin-coated plates
using Knock-out DMEM (Life Technologies) supplemented with 15% FBS (Life
Technologies) and LIF. Before each PGCLC differentiation, ESC were adapted to 2i
media (serum-free N2B27 medium supplemented with MEK inhibitor PD0325901
[0.4 μM, Miltenyi Biotec], GSK3β inhibitor CHIR99021 [3 μM, Amsbio], and LIF)
for at least 4 days in gelatin-coated tissue culture plates83. All measurements
described in the manuscript for ESC were performed under 2i conditions.
For EpiLC and PGCLC differentiation, the protocols from83 were followed. For
the EpiLC differentiation, 6-well plates were coated with 15 µg ml−1 Fibronectin
and 2 × 105 2i ESC were differentiated in N2B27 media supplemented with
20 ng ml−1 Activin A, 12 ng ml−1 bFGF, and 10 µl ml−1 KSR for two days (unless
indicated otherwise for particular experiments). For the PGCLC differentiation,
EpiLC or EpiSC were plated at a density of 2 × 104 cells ml−1 and cultured as
embryoid bodies (EB) on Ultra-Low attachment multiwell plates (Corning®
Costar®) in GK15 medium supplemented with growth factors (0.5 µg ml−1 BMP4,
0.1 µg ml−1 SCF, 1000 Uml−1 LIF and 50 ng ml−1 EGF, no BMP8a). Unless
otherwise indicated, PGCLC were typically analyzed after four days.
EpiSC differentiation was performed according to84. 2i ESC were plated at a
density of 2.5 × 105 cells ml−1 on plates coated with 15 µg ml−1 Fibronectin and
differentiated into EpiSC by passaging them in N2B27 media supplemented with
20 ng ml−1 Activin A and 12 ng ml−1 bFGF for at least eight days or as indicated in
the results section for particular experiments.
Enhancer and gene deletions with CRISPR/Cas9. Pairs of gRNAs flanking
each of the selected enhancers/genes were designed with benchling (https://
www.benchling.com). ESC were transfected with pairs of gRNA-Cas9 expressing
vectors85 specific for each enhancer/gene using Lipofectamine 3000 (invitrogen).
After transfection and puromycin selection, single cells were seeded into a 96
well plate to derive clonal cell lines. Then, clonal lines were genotyped by PCR
and the presence of the intended deletions in each clonal line was verified by
Sanger-sequencing. gRNA sequences and genomic coordinates of the different
deletions are listed in Supplementary Data 6.
Generation of the Mll3/4 dCD, Mll3/4 dCT and Mll4 CT ESC lines. The Mll3/4
dCD ESC line was previously generated and described38. The Mll3/4 dCT and Mll4
CT ESC lines were also generated as described in38. Briefly, R1 ESC were co-
transfected with a 200 bp single-stranded oligonucleotide donor template harbor-
ing the desired point mutations and a vector coexpressing Cas9 and gRNAs tar-
geting Mll3 and Mll4. After 48 h, single GFP+ cells were sorted into 96 well plates
coated with fibronectin (5 mgml−1). The resulting clonal ESC lines were genotyped
by PCR amplification of a region spanning the cleavage site, followed by digestion
with a restriction enzyme predicted to only cut the wild-type PCR products. Once
candidate ESC lines were selected, the presence of the intended Mll3/4 mutations
was confirmed by Sanger sequencing.
Ectopic and inducible expression of candidate transcription factors. Mouse
Prdm14 and Nanog cDNAs were amplified and cloned into a Doxycycline (Dox)-
inducible piggyBac vector86 enabling the ectopic expression of selected genes fused
with an HA-tag at their C-terminus. The resulting piggyBac vectors were trans-
fected together with a Super PiggyBac Transposase expressing vector (Systems
Fig. 7 Chromatin features of PGCLC enhancers in vivo. a DNAse-seq levels for Group I and II PGCLC enhancers in PGCs from E9.5 and E10.5 mouse
embryos67. Scales are in RPGC. b CpG methylation levels for Group I and II PGCLC enhancers in E4.5, E5.5, and E6.5 mouse epiblasts68. P-values were
calculated using paired two-sided Wilcoxon tests. Scales: percentage of methylated CpGs. c mCpG heterogeneity was estimated based on the mCpG
dissimilarity concept. For each pairwise comparison, the methylation status of CpGs covered in the two cells being compared is considered (blue lollipops).
If two cells show the same or different methylation status they receive a value of 0 (similarity) or 1 (dissimilarity), respectively. The mean of all pairwise
comparisons reflects CpG methylation heterogeneity. d Heatmap showing mCpG heterogeneity within PGCLC enhancers between pairs of individual cells.
mCpG heterogeneity values are presented with a blue-red scale (blue: similar; red: dissimilar). The developmental stages of the investigated cells (E4.5,
E5.5, or E6.5) and the average CpG methylation (blue-orange scale) measured for all PGCLC enhancers within each cell (n= 261 cells) are shown above
the heatmap. e CpG methylation heterogeneity was measured in E4.5, E5.5, and E6.5 epiblast cells for all covered CpGs in the mouse genome as well as
within EpiLC, EpiSC, and PGCLC enhancers. The horizontal lines in the boxplots indicate the median, the boxes the first and third quartiles, and the whiskers
the ± 1.5 × interquartile range. f Comparison of the single-cell CpG methylation of Group I PGCLC enhancers and the single-cell RNA expression of genes
linked to them (n= 256) in E4.5, E5.5, and E6.5 epiblasts. fpkm: Fragments per kilobase per million mapped reads. g Model illustrating the potential
relevance of the partial decommissioning of Group I PGCLC enhancers for in vitro germline competence. The persistence of H3K4me1 within PGCLC
enhancers in EpiLC might protect them from heterochromatinization (H3K9me3 and CpG methylation) and render them accessible and responsive to
transcriptional activators. In turn, this can confer germline competence by facilitating PGCLC enhancer (re)activation during PGCLC differentiation.
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Bioscience) and a Tet transactivator. After transfection, single cells were seeded into
a 96 well plate to derive clonal ESC lines. The clonal ESC lines with the lowest
expression of the transgenic genes in the absence of Dox were selected. To evaluate
the effects of PRDM14 and NANOG ectopic expression on PGCLC specification,
1 µg ml−1 Dox was added once PGCLC differentiation was started. To investigate
the effects of the ectopic expression of PRDM14 or NANOG in EpiLC and EpiSC,
1 µg ml−1 Dox was added 18 h before the cells were collected for downstream
ChIP-seq experiments (i.e. EpiLC differentiation was initiated, after 30 h Dox was
added and cells were collected after 48 h; EpiSC were maintained in differentiation
media for at least eight passages and then treated with Dox for 18 h).
Quantification of PGCLC by flow cytometry. In general, PGCLC were quantified
using antibody staining and flow cytometry83. Briefly, after four days of PGCLC
differentiation, the resulting EB were dissociated and stained for 45 min with
antibodies against CD61 (Biolegends, cat#104307; dilution 1:500) and CD15
(Thermo Fisher, cat#50-8813-41; dilution 1:200) conjugated with PE and Alexa
Fluor 647, respectively. All PGCLC quantifications were performed using the FACS
CantoII Cytometer (BD Bioscience) equipped with the BD FACSDiva Software.
PGCLC sorting was performed on a FACS AriaIII cell sorter (BD Bioscience) and
the data were analyzed with FlowJo (Version 10.6.1).
ATAC-seq. The ATAC-seq protocol was adapted from87 using 3.8 × 104 and
5.0 × 104 cells for the two replicates generated for each of the investigated cell types,
respectively. Briefly, the cells were lysed in lysis buffer (10 mM Tris-HCl, pH 7.4,
10 mM NaCl, 3 mM MgCl2, 0.1% IGEPAL CA-630) supplemented with freshly
added protease inhibitor for 15 min. Following centrifugation, the pellet was
resuspended in a Tn5 transposase reaction mix (Illumina) for 30 min at 37 °C.
Following DNA purification with the MinElute PCR purification kit (Qiagen),
libraries were prepared with the Nextera DNA library prep kit (Illumina).
ChIP-seq and ChIPmentation. Cells were cross-linked with 1% formaldehyde for
10 min, followed by quenching with 0.125 M glycine, harvesting, and washing in
PBS containing protease inhibitors. The cells were sequentially lysed in three
buffers (lysis buffer 1: 50 mM HEPES, 140 mM NaCl, 1 mM EDTA, 10% glycerol,
0.5% NP-40, 0.25% TX-100; lysis buffer 2: 10 mM Tris, 200 mM NaCl, 1 mM
EDTA, 0.5 mM EGTA; lysis Buffer 3: 10 mM Tris, 100 mM NaCl, 1 mM EDTA,
0.5 mM EGTA, 0.1% Na-Deoxycholate, 0.5% N-lauroylsarcosine) with rotation for
10 min in between. Then, the chromatin was sonicated with the Epishear™ Probe
Sonicator (Active Motif) with 20 s ON and 30 s OFF for 8 cycles. After cen-
trifugation, the supernatant was divided into input and ChIP samples. The ChIP
samples were incubated with specific antibodies (Supplementary Data 6) overnight,
followed by immunoprecipitation with Dynabeads Protein G beads (invitrogen).
Next, the beads were washed with RIPA buffer (50 mM Hepes, 500 mM LiCl, 1 mM
EDTA, 1% NP-40, 0.7% Na-Deoxycholate) on a magnet, eluted (50 mM Tris,
10 mM EDTA, 1% SDS), and reverse cross-linked at 65 °C overnight in parallel
with the input. Finally, DNAs were purified with the ChIP DNA Clean & Con-
centrator (Zymo Research) and analyzed by qPCR (Primers in Supplementary
Data 6), or ChIP libraries were generated with the TruSeq kit (Illumina).
When ChIP-seq profiles were generated from low cell numbers (e.g. d4 EB
obtained with the PGCLC differentiation protocol), the ChIPmentation protocol
described by Schmidl et al. 201588 was used. Following immunoprecipitation with
Dynabeads Protein G beads (invitrogen) in PCR tubes, samples were subject to
Tagmentation (5 µl Tagmentation Buffer, 1 µl Tagmentation DNA Enzyme
(Illumina), 19 µl Nuclease free water) in order to incorporate sequencing adapters.
Lastly, DNAs were eluted from the beads and used for library preparation with the
Nextera DNA library preparation kit (Illumina).
Locus-specific bisulfite sequencing. Genomic DNA was purified with phenol-
chloroform and subjected to bisulfite conversion according to the EZ DNA
Methylation-Direct™ Kit (Zymo Research). Then, primer pairs specific for each
investigated enhancer were used for PCR amplification with the EpiTaq HS
polymerase (TaKaRa). Finally, the resulting amplicons were gel-purified, subjected
to blunt-end cloning, and analyzed by Sanger sequencing. The target sequence and
the bisulfite primer for the selected PGCLC enhancers are listed in Supplementary
Data 6.
ChIP-bisulfite sequencing. ChIP-bisulfite experiments were performed as
described in89 with slight modifications. Firstly, the ChIP protocol described above
was followed. After the final DNA purification, all the resulting H3K4me1 and
H3K4me2 ChIP DNAs and 200 ng of the corresponding input DNA were subjected
to bisulfite conversion according to the EZ DNA Methylation-Direct™ Kit (Zymo
Research). Then, the subsequent amplification, purification, and sequencing steps
were performed as described for the locus-specific bisulfite sequencing
experiments.
Genome-wide bisulfite sequencing. Bisulfite sequencing libraries were prepared
from column-purified DNA of d2 EpiLC using the PBAT method90. Briefly, for the
bisulfite conversion the instructions of the EZ Methylation Direct MagPrep Kit
(Zymo) were followed. After purification, bisulfite-converted DNAs were eluted
from MagBeads directly into 39 µl of first-strand synthesis reaction master mix (1×
Blue Buffer (Enzymatics), 0.4 mM dNTP mix (Roche), 0.4 µM 6NF preamp oligo
(IDT)), heated to 65 °C for 3 min and cooled on ice. 50 U of klenow exo- (Enzy-
matics) was added and the mixture incubated on a thermocycler at 37 °C for
30 min after slowly ramping from 4 °C. Reactions were diluted to 100 µl and 20 U
of exonuclease I (NEB) added and incubated at 37 °C before purification using a
0.8:1 ratio of AMPure XP beads. Purified products were resuspended in 50 µl of
second strand mastermix (1× Blue Buffer (Enzymatics), 0.4 mM dNTP mix
(Roche), 0.4 µM 6NR adapter 2 oligo (IDT) then heated to 98 °C for 2 min and
cooled on ice. 50 U of Klenow exo- (Enzymatics) was added and the mixture was
incubated on a thermocycler at 37 °C for 90 min after slowly ramping from 4 °C.
Second strand products were purified using a 0.8:1 ratio of AMPure XP beads and
resuspended in 50 µl of PCR master mix (1x KAPA HiFi Readymix, 0.2 µM PE1.0
primer, 0.2 µM iTAG index primer) and amplified with 12 cycles. The final libraries
were purified using a 0.8:1 volumetric ratio of AMPure XP beads before pooling
and sequencing. All libraries were prepared in parallel with the pre-PCR pur-
ification steps carried out using a Bravo Workstation pipetting robot (Agilent
Technologies).
RNA isolation, cDNA synthesis and RT-qPCR. Total RNA from ESC, EpiLC, and
EpiSC was extracted following the protocol of the innuPREP DNA/RNA mini kit
(Analytik Jena), while for the RNA extraction from d2 EB, d4 EB and sorted
PGCLC the ReliaPrep™ RNA Miniprep Systems (Promega) was used. cDNAs were
generated using the ProtoScript II First Strand cDNA Synthesis Kit and Oligo(dT)
primers (New England Biolabs). RT-qPCR were performed on the Light Cycler
480II (Roche) with the primers listed in Supplementary Data 6 using Eef1a1 and
Hprt as housekeeping controls.
RNA-seq and scRNA-seq. Total RNA from WT and dCD EpiLC (2 replicates)
and EpiSC (2 replicates) were purified as described above. Bulk RNA-seq were
generated following the protocol of the TruSeq stranded kit (Illumina).
For scRNA-seq, EpiSC were dissociated with Accutase and all other cell types
with TripleExpress. Cells were then centrifuged and resuspended in PBS containing
0.04% BSA. Next, cells were passed through a strainer, the cell concentration was
determined and the scRNA-seq libraries were prepared using the Chromium
Single-Cell Gene Expression (10× Genomics) according to the Single-Cell 3′
Reagents Kit (v2) protocol for the single-cell experiment of the PGCLC
differentiation (Fig. 1) and the Single-Cell 3′ Reagents Kit (v3) protocol for the d4
EB from R1 WT and dCD cells (Fig. 6).
Western Blot. Nuclei were isolated by incubating cells with lysis buffer (20 mM
Tris pH 7.6, 100 mM NaCl, 300 mM sucrose, 3 mM MgCl2) containing freshly
added protease inhibitors for 10 min at 4 °C and then centrifuged for 10 min at 4 °C
and 1680 g. The resulting pellets, containing the cell nuclei, were treated with a
high salt buffer (20 mM Tris pH 8.0, 400 mM NaCl, 2 mM EDTA pH 8.0) and
disrupted with a glass homogenizer on ice. After incubation on ice for 30 min and
centrifugation (24000 × g for 20 min at 4 °C), supernatants were collected and
protein concentration was estimated by a BCA-Assay. 20 µg of the resulting protein
extracts were heated in Laemmli buffer at 95 °C for 5 min, loaded on 4–15% Mini-
PROTEAN® TGX™ Precast Protein Gels (Bio-Rad) and transferred (190 mM gly-
cine, 25 mM Tris, 20% Methanol, 0.1% SDS) to a PVDF membrane. After blocking
with 5% milk, the primary antibody (Supplementary Data 6) was incubated
overnight at 4 °C, and the secondary antibody (coupled to horseradish peroxidase
(HRP)) for 1 h at RT with washes in between. Finally, proteins were visualized
using the lumi-light plus western blotting substrate (Roche). Full scan images are
provided in the Source Data file.
scRNA-seq data processing. The 10x Genomics scRNA-seq data generated in this
study across different stages of PGCLC differentiation can be explored by opening
the.cloupe file available through GEO [https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?
acc=GSE155088] with the Loupe Cell Browser (https://www.10xgenomics.com). UMIs
were counted using NCBI:GCA_000001635.6 and cellranger-2.1.091. The resulting UMI
values were aggregated into a single matrix with default normalization
(“–normalize=mapped”) (Supplementary Data 1).
For the scRNA-seq data from E4.5–E6.5 mouse embryos43 the count matrix
(GSE121650) was normalized to FPKM (edgeR, Ensembl gene annotation, v87).
Then, the previously generated lineage assignments43 were used to solely select
epiblast cells for further analysis.
scRNA-seq data analysis. The code used to define PGCLC genes is available
through Github (https://github.com/ToreBle/Germline_competence). Briefly,
monocle292 was used to evaluate the in vitro scRNA-seq data generated across the
different PGCLC differentiation stages. Therefore, k-means clustering was per-
formed on the t-SNE plots (with k= 3 for d2 EB and k= 4 for d4 EB). From the
resulting clusters, those containing PGCLC were identified by the enrichment of
previously defined core PGC genes from d4/d6 PGCLC and E9.5 PGCs93. To
determine the cellular identity of the remaining clusters found within the EB, the
expression of lineage-specific markers identified in E8.25 mouse embryos42 was
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used. To this end, all markers with a log2FoldChange >2.5 were considered. Each
EB cluster was annotated as equivalent to the mouse embryonic tissue for which we
observed the most significant enrichment in the expression of the corresponding
marker genes.
The ESC, EpiLC, EpiSC, and PGCLC gene sets were defined by differential
expression using Seurat94 and the negbinom option for differential expression
testing. ESC, EpiLC, and EpiSC genes were determined by differential expression
between the stage indicated vs the remaining two (e.g. ESC vs. d2 EpiLC and
EpiSC) From this analysis only the genes upregulated in the particular stage
(adjusted p-value < 0.005), a high expression in the stage of interest (more than
20%, pct.1 >0.2) and a low expression distribution in the others (less than 40%,
pct.2 <0.4) were considered. Similar PGCLC genes were determined by differential
expression between the d2+ d4 PGCLC clusters and the remaining clusters from
d2 and d4 EB. Again, from this analysis only the genes upregulated in PGCLC
(adjusted p-value < 0.005) and with high expression in PGCLC (expressed in 20%
of the PGCLC) and a low expression distribution in the other analyzed cells
(expressed in less than 40% of non-PGCLC EB cells) were considered. In the case
of PGCLC genes this resulted in 389 PGCLC genes (Supplementary Data 2). To
quantify the expression of PGCLC genes in different analyses, the UMI count
matrix (of the in vitro stages) or FPKM-normalized data (of the in vivo stages)
were used to calculate the mean expression of all PGCLC genes within a cell or the
mean expression of each PGCLC gene across all cells of a stage.
For the RNA velocity analysis (Supplementary Fig. 1f), spliced and unspliced
read counts were obtained with kallisto95 and bustools96, parsed into R-3.6.1 to
create a Seurat object and t-SNE plot which was then overlaid by the RNA velocity
calculations from velocyto.R97.
The estimation of transcriptional noise for the epiblast stages in vivo and
in vitro was performed like in44. First, the 500 most variable genes for each stage
were selected and pairwise compared by Spearman correlations. Then the





) that were considered to represent transcriptional noise.
For the single-cell RNA-seq data set of the d4 EB from R1 WT and dCD cells,
single cells with a high percentage of mitochondrial gene expression were
discarded, by considering only single cells with at least 2000 expressed genes. The
clusters (Fig. 6b) were identified in the combined dataset of R1 WT and dCD cells
by shared nearest neighbor (SNN) modularity optimization-based clustering
algorithm from Seurat with a resolution of 0.3. This resulted in 9 clusters that were
classified based on the marker gene expression of E8.25 mouse embryos42. Those
clusters that did not show any specific marker gene expression from this cluster
(e.g. 2-cell-like) were identified by differentially expressed genes within the cluster.
The Prdm1orDppa3+ /Klf4- cells were defined using the following gene expression
values; Dppa3 >0.1 OR Prdm1 >1 AND Klf4 <1. The single-cell expression
correlation values were determined by the Spearman correlation of the top 1000
most variable genes in each cluster and the correlation of their expression among
the cells belonging to the same cluster.
ChIP-seq data processing. For ChIP-seq data processing, single-end reads were
mapped to the mouse genome (mm10) using BWA98. After duplication removal with
the MarkDuplicates function from the Picard tools (http://broadinstitute.github.io/
picard/), reads within blacklisted regions (https://www.encodeproject.org/annotations/
ENCSR636HFF/) were discarded and the aligned reads were normalized with
deeptools-3.3.199 to 1x sequencing depth (as RPGC: Reads per genomic content). An
overview of all the ChIP-seq experiments performed in this study is listed in Sup-
plementary Data 6 and, briefly, it includes the following datasets:
● H3K4me1 ChIP-seq experiments in ESC (n= 2), EpiLC (n= 4) and EpiSC
(n= 2) performed in R1 and E14Tg2a cell lines.
● H3K4me2 ChIP-seq experiments in ESC (n= 2), EpiLC (n= 3) and EpiSC
(n= 3) performed in R1 and E14Tg2a cell lines.
● H3K4me3 ChIP-seq experiments in ESC (n= 2), EpiLC (n= 2) and EpiSC
(n= 2) performed in R1 and E14Tg2a cell lines.
● H3K27ac ChIP-seq experiments in ESC (n= 2), EpiLC (n= 4) and EpiSC
(n= 2) performed in R1 and E14Tg2a cell lines.
● NANOG-HA ChIP-seq experiments in EpiSC were performed as two
biological replicates in E14Tg2a.
● Additional ChIP-seq experiments were performed as single replicates
(Supplementary Data 6).
All the processed ChIP-seq data can be explored using the following UCSC
browser sessions:
- Comparison of the pluripotent stages (related to Figs. 2, 3): http://genome-
euro.ucsc.edu/s/Tore/Comparison%20of%20the%20pluripotent%20stages
- PRDM14/NANOG overexpression (related to Fig. 4): http://genome-euro.
ucsc.edu/cgi-bin/hgTracks?hgS_doOtherUser=submit&hgS_otherUserName=
Tore&hgS_otherUserSessionName=PRDM14%2FNANOG%20overexpression




ATAC-seq data processing. ATAC-seq experiments were performed as two
biological replicates for each of the investigated cell types (i.e. ESC, EpiLC, EpiSC).
For ATAC-seq data processing, paired-end reads were mapped to the mouse
genome (mm10) using BWA98. Read duplicates and reads within blacklisted
regions were discarded. Given the concordance of the ATAC-seq replicates
(Spearman correlation of a 2 kb window for ESC: 0.86; EpiLC: 0.88; EpiSC: 0.86),
BAM files for each stage were merged and converted into bigWig files by nor-
malization to 1× sequencing depth with deeptools-3.3.199. The processed ATAC-
seq data can be also found in the UCSC browser sessions mentioned above.
Enhancer definition. The code used to define enhancers is available through
Github (https://github.com/ToreBle/Germline_competence).
PGCLC enhancers: The H3K27ac ChIP-seq data (SOLiD sequencing) from d2
and d6 sorted PGCLC15 were aligned with the default settings of novoalignCS
(V1.06.09, Novocraft Technologies). For visualization, replicate BAM files for each
stage were merged and normalized to 1 x sequencing depth. Briefly, H3K27ac peaks
were called from both replicates of d6 PGCLC with MACS2100 using broad settings
(--broad -m 5 50 --fix-bimodal --extsize 200) and q-values <1 × 10−3. Next, all
peaks within a distance of 1 kb from both d6 PGCLC replicates were merged with
bedtools (https://github.com/arq5x/bedtools2). The resulting regions were
subtracted from blacklisted and promoter regions (± 2 kb of the Ensembl gene
annotation, v86) with bedtools (Supplementary Fig. 2a). PGCLC enhancers were
defined as the subset of the distal H3K27ac peaks identified in d6 PGCLC that
could be physically linked to PGCLC genes according to capture HiC data
generated in ESC by47 (Supplementary Data 1). Thereby, distal d6 PGCLC
H3K27ac peaks and PGCLC genes were linked if the two anchors of a Capture HiC
interaction occurred within 1 Kb of a d6 PGCLC H3K27ac peak and 3 Kb of the
PGCLC gene TSS.
For the statistical comparisons of epigenetic signals within PGCLC enhancers in
different cell types, we first determined the average signals of the ChIP-seq, ATAC-
seq, or genome-wide CpG bisulfite sequencing within ± 1 kb of the PGCLC
enhancers in d2 EpiLC and EpiSC using deeptools-3.3.199. Then, the effect size of
paired Wilcoxon tests were calculated by dividing the z-statistics by the square
roots of the sample sizes using rstatix and boots.ci for the approximation of the
confidence intervals (confidence level: 0.95).
EpiLC/EpiSC enhancers: Briefly, H3K27ac peaks were called in both cell types
separately with MACS2100 using broad settings (--broad -m 5 50 --fix-bimodal
--extsize 200) and q-values < 1 × 10−3. The resulting regions were subtracted from
blacklisted and promoter regions (± 2 kb of the Ensembl gene annotation, v86)
using bedtools. EpiLC and EpiSC enhancers were obtained from these regions by
selecting only H3K27ac peaks located within 500 kb of the gene sets defined by
single-cell RNA-seq for each cell type. The enhancer assignment to the proximal
genes was done with GREAT-4.0.4101 and only enhancers with a minimum
distance of 3.5 kb to the nearest transcription start site (TSS) were considered.
CpG methylation analysis. The analysis of the local bisulfite sequencing experi-
ments performed for selected PGCLC enhancers was evaluated with BISMA102.
Genome-wide DNA methylation data was analyzed with Bismark103.
However, as the considered data sets were prepared with slightly different
protocols, the preprocessing steps were adjusted accordingly: For the whole-
genome bisulfite sequencing data from 2i ESC (GSE41923), d2 EpiLC, and EpiSC
(GSE70355), the adapter trimming was performed with Trim Galore (http://
www.bioinformatics.babraham.ac.uk/projects/trim_galore/) using the default
settings; for data sets generated by post bisulfite adapter tagging (pbat), either 9
(data from d2 EpiLC and PGCLC (DRA003471)) or 6 bp (genome-wide
methylation data generated in this study) were removed. The DNA methylation
data from E4.5–E6.5 epiblasts were generated by STEM-seq (GSE76505), and, in
this case, adapter sequences were removed with cutadapt104 and Trim Galore,
respectively. For all the previous samples, reads were mapped with Bismark-
v0.16.1103 and bowtie2-2.2.9105, using the -pbat setting for the STEM-seq and
pbat samples. For paired-end pbat samples the unmapped reads were remapped
as single-end reads. Then, for each cell type all available datasets were combined
to estimate the CpG methylation levels with the Bismark methylation extractor.
Finally, only CpGs with a coverage of 3−100 reads were considered.
CpG methylation heterogeneity and scNMT-seq analysis. With the scNMT-seq
method the transcriptome, methylome (CpG methylation), and chromatin acces-
sibility (GpC methylation) are recorded from the same single-cell106. Among all the
single cells analyzed in E4.5, E5.5, and E6.5 mouse embryos by43, we only con-
sidered those assigned to the epiblast by scRNA-seq (https://github.com/
rargelaguet/scnmt_gastrulation). Then, epiblast cells were additionally filtered
according to their methylome (GSE121690) and only cells with a CpG coverage
>102 at PGCLC enhancers were considered. This resulted in 258 epiblast cells from
E4.5, E5.5, and E6.5 with high-quality single-cell CpG methylation data.
The single-cell CpG methylation for each cell was stored in a bedGraph file.
From each bedGraph file the genome-wide CpG methylation levels of individual
cells were determined as the mean methylation of all covered CpGs in each single-
cell. For the analysis of mCpG levels and CpG coverage within PGCLC enhancer
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Group I, the genome-wide bedGraph files were subtracted to obtain bedGraph
files with the PGCLC enhancer regions (Supplementary Data 3) using bedtools
(https://github.com/arq5x/bedtools2) from which the mean methylation of all
covered CpGs was determined in each single-cell.
CpG methylation heterogeneity was estimated with the PDclust package70. The
number of CpGs covered in each pair of cells resulted in approximately 150 CpGs
for each pairwise comparison when PGCLC enhancers were considered. Then, the
average of the absolute difference in the methylation values for all the CpGs
covered for each pairwise comparison were computed as a dissimilarity matrix.
For the scRNA-seq data, the mean expression of all PGCLC genes (FPKM-
normalized) linked to Group I PGCLC enhancers was determined per cell.
Bulk RNA-sequencing. Public available RNA-seq data generated across different
time-points of EpiLC differentiation107, Otx2-/- EpiLC57, and Prdm14-/- EpiLC14
were mapped with STAR108 to the mouse reference genome (Ensembl gene
annotation, v99), and reads within genes were counted with featureCounts109. The
rlog normalization was generated with DESeq2110.
For the bulk RNA-seq data generated in R1 WT and dCD cells, we analyzed
three replicates for R1 WT and the dCD ESC previously generated by Dorighi
et al., 2017, two replicates for R1 WT and dCD d2 EpiLC, and two replicates for
R1 WT and dCD EpiSC. The transcript abundance was determined with the
bootstrap mode of kallisto (-b 100)95 and the differential expression analyses
were performed with sleuth on the gene-level (Ensembl gene annotation,
v96)95,111.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
The data that support this study are available from the corresponding authors upon
reasonable request. The NGS data generated in this study have been deposited in the
GEO database under accession code GSE155089. The enhancer sets of this study are
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